All In Biotech

Free tool

FAERS Monitor: Vitrakvi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210861 or its brand name (Vitrakvi, Larotrectinib Sulfate). Reports on generic versions are filed under their own applications.

Reports

896

Serious

668

75% of reports

Hospitalization

173

Death reported

163

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dizziness62
  • fatigue62
  • drug ineffective61
  • death52
  • neuropathy peripheral45
  • pain44
  • disease progression38
  • nausea38
  • off label use38
  • myalgia27
  • vomiting27
  • diarrhoea23
  • malignant neoplasm progression23
  • anaemia21
  • headache21

Reports by year received

View as table
YearReports
201997
2020138
2021147
2022137
2023138
202493
2025100
202646

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,263 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
neuropathy peripheralSignal4511.18.4406
disease progressionSignal387.55.5210
malignant neoplasm progressionSignal235.33.576
myalgiaSignal273.72.652
dizzinessSignal622.92.378
anaemiaSignal212.61.719
fatigue621.91.525
pain441.71.312
death521.41.16
vomiting271.30.92
nausea381.10.80
drug ineffective611.10.90
off label use381.00.70
diarrhoea230.80.61
headache210.80.51

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.